ACT Genomics has announced a major enhancement to its ACTDrug® series, a next-generation sequencing (NGS) genomic profiling service for cancer patients. The upgraded panel now analyzes 101 clinically relevant genes and promises a rapid seven-working-day turnaround time. This development is designed to equip physicians with comprehensive genomic data to guide treatment decisions for newly diagnosed advanced or metastatic cancers.
Accelerating Precision Oncology
The upgraded ACTDrug® series aims to provide crucial genomic insights at the point of diagnosis and initial treatment planning. Early treatment decisions can profoundly influence patient outcomes, making timely information essential for effective care. With broader gene coverage and faster reporting, clinicians can more efficiently identify key biomarkers and consider targeted therapies earlier.
The expanded 101-gene panel offers a comprehensive analysis of biomarkers associated with various treatment pathways. It includes markers for targeted therapies, immunotherapy response, and potential drug resistance mechanisms. This broad scope allows for a more nuanced understanding of a patient's tumor, facilitating the creation of highly personalized treatment strategies.
A Legacy of Clinical Application
With nearly a decade of real-world application, the ACTDrug® service has a proven track record in clinical settings. It has supported more than ten thousand cases across major medical centers in Taiwan and throughout Asia. The service has earned recognition from clinicians for its relevance and practical utility in guiding effective treatment selection.
ACT Genomics leverages proprietary bioinformatics pipelines and curated clinical knowledge bases to power its service. This advanced infrastructure translates complex genomic data into clear, physician-friendly reports. The goal is to deliver actionable insights that can be seamlessly integrated into routine clinical practice for improved decision-making.
Specialized Solutions and Global Reach
In addition to its comprehensive panel, ACT Genomics provides specialized subpanels for specific cancer types. These include targeted tests for breast, lung, and gastrointestinal cancers, with gene content aligned to current treatment guidelines. These disease-specific options offer faster turnaround times and a focused approach for clinicians.
As a member of the Delta Group, ACT Genomics is committed to advancing precision oncology on a global scale. The worldwide release of the enhanced ACTDrug® series underscores this commitment to supporting cancer care internationally. However, service availability may vary between regions depending on local regulatory requirements and laboratory arrangements.
The enhancement of the ACTDrug® series marks a significant step forward in the field of precision oncology. By offering a more comprehensive gene panel with a faster turnaround, ACT Genomics is empowering clinicians with critical tools for personalized medicine. This advancement promises to improve cancer care by providing timely, reliable, and clinically meaningful genomic insights to guide treatment worldwide.